Aurinia Pharmaceuticals
AUPH
16.01
+0.32
+2.04%
Aurinia Pharmaceuticals
US · AUPH
#2749 by market cap
Listed 1970
16.01
+0.32
+2.04%
Live - 5344 symbols - heartbeat 475s ago
· 2026-10-08 08:17
Pre-market
16.05
+0.25%
After-hours
16.01
0.00%
- Market cap
- 2.13B
- P/E (TTM)i
- 7.02
- P/Bi
- 3.46
- EPSi
- 2.07
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on AUPH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.78, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.38% YoY
Margins
- Gross margin
- 88.46%
- Operating margin
- 37.65%
- Net margin
- 101.47%
Key ratios & quality
- Altman Z-Scorei
- 7.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 463.00K | 318.00K | 50.12M | 45.61M | 134.03M | 175.51M | 235.13M | 283.06M |
| Gross profit | -- | 318.00K | 50.12M | 44.51M | 128.37M | 161.37M | 206.89M | 250.39M |
| Selling & admin expenses | 13.69M | 22.34M | 97.27M | 173.54M | 196.37M | 195.04M | 172.03M | 101.79M |
| Research & development | 41.38M | 52.87M | 50.33M | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
| Operating profit | -55.91M | -90.94M | -104.29M | -180.74M | -111.47M | -91.69M | 18.42M | 106.56M |
| Pretax profit | -53.01M | -88.24M | -102.77M | -180.21M | -106.35M | -77.47M | 7.45M | 114.16M |
| Tax | 73.00K | 144.00K | -94.00K | 760.00K | 1.83M | 551.00K | 1.70M | -173.05M |
| Net profit | -53.08M | -88.39M | -102.68M | -180.97M | -108.18M | -78.02M | 5.75M | 287.20M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 2 |
| Diluted EPS | -0.63 | -0.95 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.07 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 62.47M | 70.01M | 73.47M | 77.11M | 77.71M | 83.22M |
| Gross profit | 53.89M | 62.89M | 65.29M | 68.32M | 71.20M | 76.67M |
| Selling & admin expenses | 20.34M | 26.02M | 26.18M | 29.26M | 22.03M | 23.51M |
| Research & development | 5.74M | 7.43M | 8.44M | 10.90M | 7.47M | 13.05M |
| Operating profit | 23.38M | 20.20M | 29.75M | 33.24M | 41.42M | 46.34M |
| Pretax profit | 24.35M | 22.16M | 31.96M | 35.69M | 43.93M | 48.79M |
| Tax | 1.01M | 643.00K | 411.00K | -175.10M | 9.57M | 11.37M |
| Net profit | 23.34M | 21.51M | 31.55M | 210.79M | 34.36M | 37.41M |
| Basic EPS | 0 | 0 | 0 | 2 | 0 | 0 |
| Diluted EPS | 0.16 | 0.16 | 0.23 | 1.53 | 0.25 | 0.28 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 132.85M | 315.14M | 419.43M | 513.32M | 442.54M | 424.80M | 446.60M | 491.97M |
| Cash & ST investments | 125.86M | 306.02M | 398.33M | 466.08M | 389.39M | 350.49M | 358.48M | 398.00M |
| Inventory | -- | 0 | 13.93M | 19.33M | 24.75M | 39.71M | 39.23M | 45.69M |
| Total assets | 145.86M | 324.30M | 463.66M | 543.37M | 470.86M | 548.06M | 550.65M | 751.59M |
| Total current liabilities | 7.26M | 11.30M | 32.00M | 40.65M | 46.11M | 77.19M | 97.76M | 93.72M |
| Short-term debt | -- | -- | 788.00K | 1.06M | 936.00K | 15.60M | 15.07M | 17.59M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 33,288,000.00 | 25,701,000.00 | 55,911,000.00 | 64,276,000.00 | 65,425,000.00 | 170,108,000.00 | 173,167,000.00 | 170,256,000.00 |
| Total equity | 112.58M | 298.60M | 407.75M | 479.09M | 405.44M | 377.95M | 377.48M | 581.33M |
| Retained earnings | -415.96M | -472.48M | -575.16M | -756.12M | -864.30M | -942.32M | -936.57M | -649.37M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 405.76M | 408.97M | 438.74M | 491.97M | 480.24M | 541.32M |
| Cash & ST investments | 312.90M | 315.13M | 351.81M | 398.00M | 378.78M | 443.12M |
| Inventory | 46.20M | 46.50M | 44.79M | 45.69M | 46.41M | 45.15M |
| Total assets | 504.85M | 502.56M | 527.53M | 751.59M | 724.00M | 792.26M |
| Total current liabilities | 68.41M | 78.27M | 76.22M | 93.72M | 86.56M | 99.89M |
| Short-term debt | 15.54M | 17.21M | 17.37M | 17.59M | 18.14M | 18.18M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 154,660,000.00 | 167,261,000.00 | 161,757,000.00 | 170,256,000.00 | 156,371,000.00 | 177,398,000.00 |
| Total equity | 350.19M | 335.30M | 365.77M | 581.33M | 567.63M | 614.86M |
| Retained earnings | -913.23M | -891.71M | -860.16M | -649.37M | -615.01M | -577.60M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -51.61M | -63.59M | -69.86M | -157.69M | -79.53M | -33.46M | 44.39M | 135.66M |
| Depreciation & amortization | 1.31M | 1.17M | 1.37M | 2.76M | 2.71M | 11.65M | 19.45M | 19.45M |
| Free cash flow | -51.69M | -63.69M | -77.20M | -159.19M | -79.82M | -34.18M | 44.11M | 135.41M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 223.12M | 187.73M | 196.74M | 0 | 0 | -40.24M | -98.16M |
| Ending cash balance | 117.97M | 306.02M | 272.35M | 231.90M | 94.17M | 48.88M | 83.43M | 80.21M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.30M | 44.24M | 44.45M | 45.67M | 32.56M | 52.57M |
| Depreciation & amortization | 4.86M | 4.86M | 4.87M | 4.86M | 4.82M | 4.83M |
| Free cash flow | 1.28M | 44.14M | 44.38M | 45.60M | 32.52M | 52.57M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -46.92M | -42.56M | -8.67M | 0 | -36.17M | -38.72M |
| Ending cash balance | 66.43M | 53.00M | 73.19M | 80.21M | 41.01M | 179.83M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -46.08 | -64.15 | -30.14 | -40.81 | -24.46 | -19.92 | 1.52 | 59.91 |
| ROA %i | -38.20 | -52.42 | -25.98 | -35.94 | -21.33 | -15.31 | 1.05 | 44.11 |
| ROIC %i | -47.25 | -65.16 | -29.85 | -40.12 | -24.90 | -20.08 | -0.78 | 50.30 |
| 5-year avg ROE %i | -68.62 | -60.76 | -52.75 | -44.24 | -35.10 | -31.45 | -22.55 | -4.75 |
| EBIT margin %i | -12,129.16 | -38,887.74 | -194.50 | -396.31 | -83.17 | -42.56 | 5.22 | 41.86 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 18.76 | 47.84 |
| Current ratioi | 18.30 | 27.90 | 13.11 | 12.63 | 9.60 | 5.50 | 4.57 | 5.25 |
| Quick ratioi | 17.36 | 27.13 | 12.45 | 11.85 | 8.74 | 4.85 | 4.04 | 4.69 |
| Debt / assetsi | -- | 0.00 | 1.81 | 1.61 | 1.72 | 17.81 | 14.41 | 9.95 |
| LT debt / equityi | -- | -- | 1.87 | 1.60 | 1.76 | 21.70 | 17.03 | 9.84 |
| Interest coveragei | -- | -3,170.85 | -- | -- | -- | -26.92 | 2.54 | 27.36 |
| Revenue CAGR (3Y) %i | 25.36 | 22.50 | 393.10 | 361.82 | 649.76 | 51.86 | 72.76 | 28.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.23 | 17.33 | 20.65 | 59.91 | 64.98 | 66.12 |
| ROA %i | 7.80 | 11.82 | 14.46 | 44.11 | 48.54 | 48.52 |
| ROIC %i | 6.62 | 11.63 | 14.88 | 50.30 | 54.99 | 56.26 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.77 | 25.77 | 31.63 | 41.86 | 46.27 | 52.80 |
| FCF / sales %i | 25.88 | 35.53 | 45.10 | 47.84 | 55.87 | 56.20 |
| Current ratioi | 5.93 | 5.23 | 5.76 | 5.25 | 5.55 | 5.42 |
| Quick ratioi | 5.16 | 4.54 | 5.02 | 4.69 | 4.94 | 4.85 |
| Debt / assetsi | 15.43 | 16.28 | 14.83 | 9.95 | 9.48 | 8.10 |
| LT debt / equityi | 17.81 | 19.27 | 16.64 | 9.84 | 8.90 | 7.47 |
| Interest coveragei | 10.05 | 14.77 | 18.98 | 27.36 | 32.28 | 40.06 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 08:17:43 · For reference only, not investment advice and not tailored to your situation.